SGLT-2抑制剂与GLP-1受体激动剂治疗2型糖尿病的系统综述与网络荟萃分析
两药均降低全因死亡、心血管死亡、非致死性心肌梗死和肾衰竭(高确定性证据),但SGLT-2抑制剂更减少心衰住院,GLP-1受体激动剂更减少非致死性卒中。绝对获益随患者风险升高而增大。
要点
- SGLT-2抑制剂与GLP-1受体激动剂均降低全因死亡、心血管死亡、非致死性心梗和肾衰竭。
- SGLT-2抑制剂减少心衰住院优于GLP-1受体激动剂,后者减少非致死性卒中更优。
- SGLT-2抑制剂致生殖道感染(高确定性),GLP-1受体激动剂或致严重胃肠道事件(低确定性)。
核心结论
- 在2型糖尿病患者中,SGLT-2抑制剂和GLP-1受体激动剂降低心血管和肾脏结局,但获益与危害存在差异。
- 绝对获益由患者个体风险特征决定,对临床实践有明确意义。
研究设计与样本
- 系统综述与频率学随机效应网络荟萃分析,检索Medline、Embase和Cochrane CENTRAL至2020年8月11日。
- 纳入比较SGLT-2抑制剂或GLP-1受体激动剂与安慰剂、标准治疗或其他降糖治疗的随机对照试验,随访≥24周。
主要发现
- 两药均降低全因死亡、心血管死亡、非致死性心肌梗死和肾衰竭(高确定性证据)。
- SGLT-2抑制剂减少心衰住院优于GLP-1受体激动剂;GLP-1受体激动剂减少非致死性卒中优于SGLT-2抑制剂(后者似无效果)。
- SGLT-2抑制剂导致生殖道感染(高确定性);GLP-1受体激动剂可能致严重胃肠道事件(低确定性)。
- 低确定性证据提示两药可能降低体重。
- SGLT-2抑制剂使每1000例患者5年死亡减少3至40例(随风险从低到极高变化)。
关键数值与推荐
- 纳入标准:成人2型糖尿病患者,随访≥24周的随机对照试验。
- 绝对效应按每1000例治疗5年计算,风险分层为极低危(无心血管危险因素)、低危(≥3个心血管危险因素)、中危(心血管疾病)、高危(慢性肾脏病)、极高危(心血管疾病合并肾脏病)。
临床怎么用
- 根据患者心血管和肾脏风险特征个体化选择SGLT-2抑制剂或GLP-1受体激动剂。
- 心血管疾病患者可优先考虑SGLT-2抑制剂以减少心衰住院,卒中高风险患者可优先考虑GLP-1受体激动剂。
- 使用SGLT-2抑制剂需注意生殖道感染,使用GLP-1受体激动剂需警惕严重胃肠道事件。
局限性
- 针对截肢、失明、眼病、神经病理性疼痛或健康相关生活质量,证据很少或没有。
- 部分结局(如严重胃肠道事件、体重)的证据确定性为低。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate sodium-glucose cotransporter-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists in patients with type 2 diabetes at varying cardiovascular and renal risk. DESIGN: Network meta-analysis. DATA SOURCES: Medline, Embase, and Cochrane CENTRAL up to 11 August 2020. ELIGIBILITY CRITERIA FOR SELECTING STUDIES: Randomised controlled trials comparing SGLT-2 inhibitors or GLP-1 receptor agonists with placebo, standard care, or other glucose lowering treatment in adults with type 2 diabetes with follow up of 24 weeks or longer. Studies were screened independently by two reviewers for eligibility, extracted data, and assessed risk of bias. MAIN OUTCOME MEASURES: Frequentist random effects network meta-analysis was carried out and GRADE (grading of recommendations assessment, development, and evaluation) used to assess evidence certainty. Results included estimated absolute effects of treatment per 1000 patients treated for five years for patients at very low risk (no cardiovascular risk factors), low risk (three or more cardiovascular risk factors), moderate risk (cardiovascular disease), high risk (chronic kidney disease), and very high risk (cardiovascular disease and kidney disease). A guideline panel provided oversight of the systematic review. RESULTS: 764 trials including 421 346 patients proved eligible. All results refer to the addition of SGLT-2 inhibitors and GLP-1 receptor agonists to existing diabetes treatment. Both classes of drugs lowered all cause mortality, cardiovascular mortality, non-fatal myocardial infarction, and kidney failure (high certainty evidence). Notable differences were found between the two agents: SGLT-2 inhibitors reduced admission to hospital for heart failure more than GLP-1 receptor agonists, and GLP-1 receptor agonists reduced non-fatal stroke more than SGLT-2 inhibitors (which appeared to have no effect). SGLT-2 inhibitors caused genital infection (high certainty), whereas GLP-1 receptor agonists might cause severe gastrointestinal events (low certainty). Low certainty evidence suggested that SGLT-2 inhibitors and GLP-1 receptor agonists might lower body weight. Little or no evidence was found for the effect of SGLT-2 inhibitors or GLP-1 receptor agonists on limb amputation, blindness, eye disease, neuropathic pain, or health related quality of life. The absolute benefits of these drugs vary substantially across patients from low to very high risk of cardiovascular and renal outcomes (eg, SGLT-2 inhibitors resulted in 3 to 40 fewer deaths in 1000 patients over five years; see interactive decision support tool (https://magicevidence.org/match-it/200820dist/#!/) for all outcomes. CONCLUSIONS: In patients with type 2 diabetes, SGLT-2 inhibitors and GLP-1 receptor agonists reduced cardiovascular and renal outcomes, with some differences in benefits and harms. Absolute benefits are determined by individual risk profiles of patients, with clear implications for clinical practice, as reflected in the BMJ Rapid Recommendations directly informed by this systematic review. SYSTEMATIC REVIEW REGISTRATION: PROSPERO CRD42019153180.
引用
- Palmer SC, Tendal B, Mustafa RA, et al. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. BMJ. 2021. PMID: 33441402. doi:10.1136/bmj.m4573
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。